Evidence map›Paper›PMID 34494025›Full record

ArticlebioRxiv : the preprint server for biology2021

Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation.

Koen K A Van Rompay, Katherine J Olstad, Rebecca L Sammak, Joseph Dutra, Jennifer K Watanabe, Jodie L Usachenko, Ramya Immareddy, Jamin W Roh, Anil Verma, Yashavanth Shaan Lakshmanappa and 21 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 5 institutions in 1 country.

Koen K A Van RompayCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Katherine J OlstadCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Rebecca L SammakCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Joseph DutraDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616.
Jennifer K WatanabeCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Jodie L UsachenkoCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Ramya ImmareddyCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Jamin W RohCenter for Immunology and Infectious Diseases, University of California, Davis, CA 95616.
Anil VermaCenter for Immunology and Infectious Diseases, University of California, Davis, CA 95616.
Yashavanth Shaan LakshmanappaCenter for Immunology and Infectious Diseases, University of California, Davis, CA 95616.
Brian A SchmidtCenter for Immunology and Infectious Diseases, University of California, Davis, CA 95616.
Clara Di GermanioVitalant Research Institute, San Francisco, CA 94118.
Nabeela RizviVitalant Research Institute, San Francisco, CA 94118.
Mars StoneVitalant Research Institute, San Francisco, CA 94118.
Graham SimmonsVitalant Research Institute, San Francisco, CA 94118.
Larry J DumontVitalant Research Institute, Denver, CO 80230; University of Colorado School of Medicine, Aurora, CO 80045.
A Mark AllenCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Sarah LockwoodCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Rachel E PollardSchool of Veterinary Medicine, University of California, Davis, CA 95616.
Rafael Ramiro de AssisVaccine Research and Development Center, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA 92697.
JoAnn L YeeCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Peter B NhamCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Amir ArdeshirCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Jesse D DeereDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616.
Jean PattersonTranslational Research Section, Virology Branch, DMID/NIAID/NIH, MD 20852.
Aarti JainVaccine Research and Development Center, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA 92697.
Philip L FelgnerVaccine Research and Development Center, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA 92697.
Smita S IyerCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Dennis J Hartigan-O'ConnorCalifornia National Primate Research Center, University of California, Davis, CA 95616.
Michael P BuschVitalant Research Institute, San Francisco, CA 94118.
J Rachel ReaderCalifornia National Primate Research Center, University of California, Davis, CA 95616.
University of California, Davis · USPacific Research Institute · USUniversity of California, Irvine · USUniversity of California, San Francisco · USVitalant · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Investigating the Role of T cells in Age-related Neurodegeneration in HIV InfectionRF1AG061001 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IYER, SWAMINATHAN SMITA, MORRISON, JOHN H · 2018 to 2022
$5.0M
Role of female genital mucosa associated CD4 T cells in vaccine-induced HIV susceptibilityR21AI143454 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IYER, SWAMINATHAN SMITA · 2019 to 2020
$623k
NIAID NIH HHS R21 AI143454NIA NIH HHS RF1 AG061001NIH HHS P51 OD011107
6 · The paper itself

Abstract

Early in the SARS-CoV-2 pandemic, there was a high level of optimism based on observational studies and small controlled trials that treating hospitalized patients with convalescent plasma from COVID-19 survivors (CCP) would be an important immunotherapy. However, as more data from controlled trials became available, the results became disappointing, with at best moderate evidence of efficacy when CCP with high titers of neutralizing antibodies was used early in infection. To better understand the potential therapeutic efficacy of CCP, and to further validate SARS-CoV-2 infection of macaques as a reliable animal model for testing such strategies, we inoculated 12 adult rhesus macaques with SARS-CoV-2 by intratracheal and intranasal routes. One day later, 8 animals were infused with pooled human CCP with a high titer of neutralizing antibodies (RVPN NT AUTHOR SUMMARY: The results of treating SARS-CoV-2 infected hospitalized patients with COVID-19 convalescent plasma (CCP), collected from survivors of natural infection, have been disappointing. The available data from various studies indicate at best moderate clinical benefits only when CCP with high titer of neutralizing antibodies was infused early in infection. The macaque model of SARS-CoV-2 infection can be useful to gain further insights in the value of CCP therapy. In this study, animals were infected with SARS-CoV-2 and the next day, were infused with pooled human convalescent plasma, selected to have a very high titer of neutralizing antibodies. While administration of CCP did not result in a detectable reduction in virus replication in the respiratory tract, it significantly reduced lung inflammation. These data, combined with the results of monoclonal antibody studies, emphasize the need to use products with high titers of neutralizing antibodies, and guide the future development of CCP-based therapies.

Identifiers

PMID34494025
PMCPMC8423222
OpenAlexW3197236115

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.